{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:52:34Z","timestamp":1791460354362,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.yrtph.2026.106237","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:43:15Z","timestamp":1788565395000},"page":"106237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond NAMs versus animal models: Context of use as the governing framework for integrated nonclinical strategies in drug development"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9297-3472","authenticated-orcid":false,"given":"Stefano","family":"Gaburro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1988-2819","authenticated-orcid":false,"given":"Brian","family":"Berridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas W.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhard von","family":"Keutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0777-7969","authenticated-orcid":false,"given":"Clive","family":"Roper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0073-9238","authenticated-orcid":false,"given":"Michael J.","family":"Fossler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-3437","authenticated-orcid":false,"given":"Jeffrey J.","family":"Bajramovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3599-9155","authenticated-orcid":false,"given":"Jean-Pierre","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9232-6041","authenticated-orcid":false,"given":"Timothy","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Bourcier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9593-3572","authenticated-orcid":false,"given":"Ronald L.","family":"Wange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3029-4815","authenticated-orcid":false,"given":"Kevin","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Phelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8756-7880","authenticated-orcid":false,"given":"Jessica H.","family":"Oliphant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Leishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1567-7918","authenticated-orcid":false,"given":"William R.","family":"Proctor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4620-1161","authenticated-orcid":false,"given":"Sean","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5716-9665","authenticated-orcid":false,"given":"Paola","family":"Dama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Nag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-3152","authenticated-orcid":false,"given":"Dominic P.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3164-3300","authenticated-orcid":false,"given":"Adrian","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2527-3526","authenticated-orcid":false,"given":"Yasunari","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9318-9310","authenticated-orcid":false,"given":"Szczepan W.","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2026.106237_bib1","series-title":"Transparency, and Translatability in Animal Research: Final Report","year":"2021"},{"key":"10.1016\/j.yrtph.2026.106237_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105345","article-title":"Gaps and challenges in nonclinical assessments of pharmaceuticals: an FDA\/CDER perspective on considerations for development of new approach methodologies","volume":"139","author":"Avila","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106237_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2022.114650","article-title":"Application of AOPs to assist regulatory assessment of chemical risks - case studies, needs and recommendations","volume":"217","author":"Bajard","year":"2023","journal-title":"Environ. Res."},{"key":"10.1016\/j.yrtph.2026.106237_bib4","article-title":"Emerging role of translational digital biomarkers within home cage monitoring technologies in preclinical drug discovery and development","volume":"15","author":"Baran","year":"2021","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.yrtph.2026.106237_bib5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/483531a","article-title":"Drug development: raise standards for preclinical cancer research","volume":"483","author":"Begley","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.yrtph.2026.106237_bib6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: the use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yrtph.2026.106237_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/toxsci\/kfae122","article-title":"An industry perspective on the FDA Modernization Act 2.0\/3.0: potential next steps for sponsors to reduce animal use in drug development","volume":"203","author":"Carratt","year":"2025","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2026.106237_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yrtph.2026.106237_bib9","series-title":"Council Directive 86\/609\/EEC of 24 November 1986 on the Approximation of Laws, Regulations and Administrative Provisions of the Member States Regarding the Protection of Animals Used for Experimental and Other Scientific Purposes","year":"1986"},{"key":"10.1016\/j.yrtph.2026.106237_bib10","article-title":"A CDER perspective: landscape of New Approach Methodologies (NAMs) submitted in drug development programs","volume":"165","author":"Dao","year":"2025","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106237_bib11","series-title":"Directive 2010\/63\/EU of the European Parliament and of the Council of 22 September 2010 on the Protection of Animals Used for Scientific Purposes","year":"2010"},{"key":"10.1016\/j.yrtph.2026.106237_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.namjnl.2026.100086","article-title":"3Rs at the European Medicines Agency: past and future activities","author":"Empl","year":"2026","journal-title":"NAM Journal"},{"key":"10.1016\/j.yrtph.2026.106237_bib13","series-title":"Communication C(2026) 3497: Roadmap Towards Phasing out Animal Testing for Chemical Safety Assessments","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106237_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1021\/acs.chemrestox.9b00499","article-title":"Quantitative systems toxicology modeling to address key safety questions in drug development: a focus of the TransQST consortium","volume":"33","author":"Ferreira","year":"2020","journal-title":"Chem. Res. Toxicol."},{"issue":"9","key":"10.1016\/j.yrtph.2026.106237_bib15","doi-asserted-by":"crossref","DOI":"10.2903\/sp.efsa.2024.EN-9008","article-title":"Proposal for a qualification system for New Approach Methodologies (NAMs) in the food and feed sector: example of implementation for nanomaterial risk assessment","volume":"21","author":"Haase","year":"2024","journal-title":"EFSA Supporting Publications"},{"key":"10.1016\/j.yrtph.2026.106237_bib16","first-page":"545","article-title":"Leveraging biomarkers and translational medicine for preclinical safety - lessons for advancing the validation of alternatives to animal testing","volume":"41","author":"Hartung","year":"2024","journal-title":"ALTEX"},{"key":"10.1016\/j.yrtph.2026.106237_bib17","article-title":"Confidence in new approach methods (NAMs): ensuring reproducibility, operationalising context-of-use and alignment with decision-making needs","volume":"166","author":"Jacobs","year":"2025","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106237_bib18","series-title":"Never-Ending Acronym Madness: Proposing a Harmonized Definition for Nams","author":"LaFollette","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106237_bib19","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1177\/1535370217700523","article-title":"Organs-on-chips: progress, challenges, and future directions","volume":"242","author":"Low","year":"2017","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.yrtph.2026.106237_bib20","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/aje\/kwad007","article-title":"Toward open and reproducible epidemiology","volume":"192","author":"Mathur","year":"2023","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.yrtph.2026.106237_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd.2017.244","article-title":"Impact of a five-dimensional framework on R&D productivity at AstraZeneca","volume":"17","author":"Morgan","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yrtph.2026.106237_bib22","series-title":"New Approach Methodologies in Regulatory Science: Proceedings of a Scientific Workshop, Helsinki","first-page":"19","year":"2016"},{"key":"10.1016\/j.yrtph.2026.106237_bib23","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.yrtph.2026.106237_bib24","first-page":"98","article-title":"Review on organs-on-chips for medicines safety assessment: a European regulatory perspective","volume":"43","author":"Portela","year":"2025","journal-title":"ALTEX"},{"key":"10.1016\/j.yrtph.2026.106237_bib25","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrd3439-c1","article-title":"Believe it or not: how much can we rely on published data on potential drug targets?","volume":"10","author":"Prinz","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yrtph.2026.106237_bib26","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1161\/CIRCRESAHA.117.310628","article-title":"Methodological Rigor in preclinical cardiovascular studies: targets to enhance reproducibility and promote research translation","volume":"120","author":"Ramirez","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.yrtph.2026.106237_bib27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.yrtph.2026.106237_bib28","series-title":"Regulation (EC) No 1907\/2006 of the European Parliament and of the Council of 18 December 2006 Concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)","year":"2006"},{"key":"10.1016\/j.yrtph.2026.106237_bib29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1021\/acs.chemrestox.0c00264","article-title":"The Tox21 10K Compound Library: collaborative chemistry advancing toxicology","volume":"34","author":"Richard","year":"2021","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106237_bib30","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1021\/acs.jcim.3c01834","article-title":"Insights into drug cardiotoxicity from biological and chemical data: the first public classifiers for FDA drug-induced cardiotoxicity rank","volume":"64","author":"Seal","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.yrtph.2026.106237_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104328","article-title":"Opportunities and insights from pharmaceutical companies on the current use of new approach methodologies in nonclinical safety assessment","volume":"30","author":"Shenton","year":"2025","journal-title":"Drug Discov. Today"},{"issue":"1-2","key":"10.1016\/j.yrtph.2026.106237_bib32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/ilar\/ilac004","article-title":"A structured approach to optimizing animal model selection for human translation - the Animal Model Quality Assessment","volume":"62","author":"Storey","year":"2021","journal-title":"ILAR J."},{"key":"10.1016\/j.yrtph.2026.106237_bib33","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.yrtph.2026.106237_bib34","series-title":"Toxicology in the 21st Century Fact Sheet","year":"2023"},{"key":"10.1016\/j.yrtph.2026.106237_bib35","series-title":"Toxicity Forecaster (Toxcast) Database","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106237_bib36","series-title":"General Considerations for the Use of New Approach Methodologies in Drug Development: Guidance for Industry (Draft Guidance, CDER)","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106237_bib37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.vascn.2009.05.011","article-title":"A framework to assess the translation of safety pharmacology data to humans","volume":"60","author":"Valentin","year":"2009","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2026.106237_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2026.106096","article-title":"Revisiting ICH S7A after 25 years: outcomes of a multi-stakeholder workshop and strategic pillars for modernizing safety pharmacology","author":"Valentin","year":"2026","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106237_bib39","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1021\/acs.est.9b06379","article-title":"Toward a global understanding of chemical pollution: a first comprehensive analysis of national and regional chemical inventories","volume":"54","author":"Wang","year":"2020","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.yrtph.2026.106237_bib40","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yrtph.2026.106237_bib41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/toxsci\/kfy270","article-title":"Today's challenges to De-Risk and predict drug safety in human \u201cMind-the-Gap.\u201d","volume":"167","author":"Weaver","year":"2019","journal-title":"Toxicol. Sci."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106237_bib42","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/toxsci\/kfae130","article-title":"A twin transition in regulatory toxicology: moving toward Chemicals 2.0 and phasing out animal testing","volume":"203","author":"Worth","year":"2025","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2026.106237_bib43","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/10915818251384270","article-title":"FDA\/CDER\/OND experience with new approach methodologies (NAMs)","volume":"45","author":"Yao","year":"2025","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106237_bib44","article-title":"Artificial intelligence-driven drug toxicity prediction: advances, challenges, and future directions","volume":"13","author":"Zhang","year":"2025","journal-title":"Toxics"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026002102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026002102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:06:06Z","timestamp":1791457566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026002102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":44,"alternative-id":["S0273230026002102"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106237","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond NAMs versus animal models: Context of use as the governing framework for integrated nonclinical strategies in drug development","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106237"}}